Molecular Insight Pharmaceuticals, Inc.
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Molecular Insight Pharmaceuticals, Inc.
The US FDA commissioner does not generally get involved with day-to-day activities, former FDA chiefs say, but perception of bias could be a lasting problem.
The US FDA commissioner does not generally get involved with day-to-day activities, former FDA chiefs say, but perception of bias could be lasting problem.
CardioDx appoints president and CEO; FDA device review veteran joins Hogan Lovells; TransEnterix names new senior surgical office; and more personnel updates from around the industry.
It used to be that the FDA's regulatory focus on therapies to treat rare diseases involved only a small segment of the agency's activities.
- Radiopharmaceuticals, Contrast Agents
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.